Sep. 12 at 12:52 PM
$VTGN $7.10 +0.45. DAC: no cost sold sufficient amount to cover initial purchase price (8.7.23). EXIT
$35.00 note: Legacy holding.
$VTG, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that PH80, one of the Company's five investigational neuroactive nasal sprays, demonstrated statistically significant improvement versus placebo in an exploratory Phase 2A study for acute management of the symptoms of premenstrual dysphoric disorder (PMDD), including negative mood and physical and behavioral symptoms.